临床抗前列腺癌核受体靶向药物的现状与展望  

Current Status and Prospects of Clinical Antiprostate Cancer Nuclear Receptor-Targeted Drugs

作　　者：王鹤 汪松 李方印[2] WANG He;WANG Song;LI Fangyin(The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Urological Surgery,Zhejiang Cancer Hospital,Hangzhou 310005,China)

机构地区：[1]浙江中医药大学第二临床医学院,浙江杭州310053 [2]浙江省肿瘤医院泌尿外科,浙江杭州310005

出　　处：《药学进展》2023年第8期608-616,共9页Progress in Pharmaceutical Sciences

摘　　要：前列腺癌是男性最常见的恶性肿瘤之一,也是导致男性死亡的主要原因之一。在过去几十年里,前列腺癌的治疗方式发生了巨大的变化。传统的治疗方法包括手术、放疗和激素治疗。然而,随着对前列腺癌发病机制的深入研究,核受体靶向药物逐渐成为前列腺癌治疗的重要组成部分。综述前列腺癌的核受体和当前已经研发的抗前列腺癌核受体靶向药物及其耐药机制和安全性,并对抗前列腺癌核受体靶向药物未来的发展进行展望。Prostate cancer is one of the most common malignancies in males and one of the leading causes of male mortality.Over the past few decades,the treatment landscape of prostate cancer has undergone significant changes.Traditional treatment modalities include surgery,radiotherapy,and hormonotherapy.However,with the in-depth study of the pathogenesis of prostate cancer,nuclear receptortargeted drugs have emerged as an important component in the treatment of prostate cancer.This article reviews the nuclear receptors within prostate cancer as well as the currently developed anti-prostate cancer nuclear receptor-targeted drugs and their resistance mechanisms and safety,along with a prospect of the future development of such drugs.

关 键 词：前列腺癌 核受体靶向药物 临床治疗 

分 类 号：R979.1[医药卫生—药品]